Business Wire

Ant International’s Antom Launches AI‑Powered MSME App for Finance and Business Operations

12.11.2025 03:00:00 CET | Business Wire | Press Release

Share

Antom, a leading provider of merchant payment and digitisation services under Ant International, today announced EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium-sized enterprises (MSMEs) move from setup to scale efficiently.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111066634/en/

The AI-powered EPOS360 provides POS system, payments, banking, lending and other growth-enabling services, offering customised support to help MSMEs operate more efficiently (Image for illustrative purposes only).

EPOS is the all-in-one SME transformation platform of Antom, one of Ant International’s major business pillars. In the first ten months of 2025, Antom recorded strong business momentum, with acquiring TPV for non-Alipay users growing over 70% year-on-year. With the launch of the new app, Antom is set to serve more MSMEs alongside enterprise customers.

In Singapore, about 99% of enterprises are SMEs. In ASEAN, MSMEs account for 97.2% – 99.9% of total establishments in ASEAN Member States. Regionally, the MSMEs contribute 44.8% to GDP. While access to finance has improved, many MSMEs still face challenges in navigating fragmented digital ecosystem, getting market insights, experiencing slow response to market volatilities, and insufficient funding channels, etc.

To tackle these pain points, the AI-powered EPOS360 app consolidates POS system, payments, banking, lending, digitisation, marketing and other growth-enabling services. Available on iOS and Android in early 2026, the app allows MSMEs to access all these services, provided by Antom, Alipay+ and ANEXT Bank under Ant International, within five minutes.

The app will help MSMEs engage more customers. It enables merchants to set up online stores across Google Maps, partnering e-wallets, and other digital channels within minutes, making it easier for consumers to find them and place orders. Merchants can also manage daily operations, inventory, and seasonal promotions, as well as get financing support from MAS-regulated ANEXT Bank without any collaterals, all at their fingertips.

In phase one, EPOS360 serves Singapore MSMEs, particularly those in retail and food & beverage, and will expand to cover Malaysia as a mini app within Touch 'n Go in early 2026. It will roll out to more markets later. The app will be available in English, Chinese, Bahasa Malaysia, Thai, and Japanese, with more languages to be added in the future.

Born with AI embedded, the app features a built-in Antom Copilot that helps merchants quickly create online stores, boost sales with omnichannel marketing, and monitor cash flow. It can suggest inventory adjustments, explain weekly performance shifts, or address payment issues. It also analyses competition and marketing campaign results to guide smarter decisions. In addition, the MSME-facing AI copilot identifies holidays, weather changes, competitors, and bundling opportunities to recommend timely promotions, generate content, and publish it across multiple digital channels.

Supported by ANEXT Bank, EPOS360 integrates banking and financing so businesses can manage funds and access credit with ease. Merchants can open a free business account, with no minimum balance or transaction fees, and earn a competitive per annum daily interest rate on eligible balances. The platform also supports expansion, allowing merchants to hold multiple currencies.

Backed by ANEXT Bank, eligible merchants may receive instant approval for a loan up to S$5,000 at sign-up to address short-term needs, with higher limits available and revenue-based financing options available as they grow.

For payments, EPOS360, supported by Antom's payment processing service provider, helps merchants accept cards and alternative payment methods for online and in-store transactions, with same-day settlement available for certain payment methods. As businesses grow, the payments setup scales with them, such as activating Alipay+ cross-border partner wallets for foreign visitors.

The app also allows merchants to pair and configure their EPOS360 Bluetap, a smart over-the-counter terminal that accepts both QR and card payments. Its QR code-based tap-to-pay feature is powered by Ant's proprietary technology.

Ian Cheong, CEO of EPOS, said: “Singapore has shown how a pro-MSME digital agenda can translate into strong economic vitality. To support MSMEs realise their full potential, we are packaging a wide range of merchant services into one AI-powered app that removes complexity and transforms everyday operations into new opportunities for growth. With EPOS360, even a neighbourhood food & beverage stall can launch an online menu, access an instant small loan, and set up a weekend promotion in minutes.”

Gary Liu, General Manager of Antom, Ant International, said: “We aim to make advanced technologies and high-quality services accessible to businesses of all sizes. Tailored-made merchant services have long felt beyond the reach of MSMEs, and EPOS360 lowers that barrier. While continuing to support cross-border merchants, we are deepening our focus on empowering local MSMEs with the same level of innovation and capability to drive sustainable growth.”

EPOS serves over 6,000 merchants in Singapore and is expanding to other markets. The platform helps businesses improve efficiency and customer engagement with intelligent sales systems, AI-driven CRM and analytics, and hardware solutions such as Soundbox and self-ordering kiosks.

To recognise outstanding MSMEs that excel in innovation, digitisation, customer experience and workplace culture, Ant International and EPOS have launched the inaugural Emerging Champions Awards in Singapore. Winners include Ai Muay Management Pte. Ltd., which won the Grand Prize in Digital Transformation for its digital transformation strategy for the six wet markets it manages, and Big Spring Day Seafood Trading Pte. Ltd., a local surimi seafood manufacturer named The Most Innovative SME for its proprietary blast-freezing technology and business model. Each winner will receive up to S$10,000 in Family Credits that can be redeemed for EPOS services to accelerate their digitisation journey.

About Antom

Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified, vertical-specific digital payment solutions to serve businesses of all sizes. Antom supports merchants to integrate over 300 payment methods, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement. To learn more, please visit https://www.antom.com/.

About EPOS

EPOSis a leading Point-of-Sale (POS) digital solutions provider based in Singapore. Supporting Ant International's mission to empower SMEs, EPOS leverages Antom’s digital capabilities as the organisation’s central hub to serve regional small and medium-sized businesses with integrated O2O digital, payment and banking solutions. For more information about EPOS360, please visit https://www.epos.com.sg/epos360/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251111066634/en/

Contacts

For media enquiries, please contact
Ant International Global Communications
pr@ant-intl.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye